Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Kayla Therapeutics
Waltham, Massachusetts, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Kailera Therapeutics is a clinical-stage biopharmaceutical company developing injectable peptide and oral peptide/small-molecule therapies for obesity and related metabolic conditions; its lead asset KAI-9531, a GLP-1/GIP receptor dual agonist licensed from Jiangsu Hengrui, has shown positive Phase 2 results in obesity and type 2 diabetes trials conducted in China.[1][2][3]
- Therapeutic areas
- EndocrinologyMetabolic Disorders
- Modalities
- PeptidesSmall molecule
- Industry
- Biotech
02
Partnerships
Jiangsu Hengrui Pharmaceuticals
Beyond the preview
Go deeper on Kayla Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kayla Therapeutics.